ESSA Pharma

ESSA Pharma Enterprise Value

Delisted

The Enterprise Value (EV) of ESSA Pharma (EPIX) as of Nov 5, 2026 is -117.48 M USD. In the previous year, Enterprise Value (EV) was -138.56 M USD — a change of -15.21% (higher).

Enterprise Value

-117.48 MUSD

YoY

-15.21%

Last updated:

Enterprise Value (EV) of ESSA Pharma is 2024 -117.48 M USD. Enterprise Value (EV) of ESSA Pharma was 2023 -138.56 M USD. It decreases by -15.21% higher compared to the previous year.

The ESSA Pharma Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2017
13.52 M USD
Jan 1, 2018
1.02 M USD
Jan 1, 2019
-40.08 M USD
Jan 1, 2020
-68.78 M USD
Jan 1, 2021
-185.38 M USD
Jan 1, 2022
-157.68 M USD
Jan 1, 2023
-138.56 M USD
Jan 1, 2024
-117.48 M USD
The ESSA Pharma Enterprise Value history
YEAREnterprise ValueYoY
-117.48 MUSD-15.21%
-138.56 MUSD-12.13%
-157.68 MUSD-14.94%
-185.38 MUSD+169.53%
-68.78 MUSD+71.61%
-40.08 MUSD-4,029.41%
1.02 MUSD-92.46%
13.52 MUSD+2,500.00%
520,000.00USD-93.43%
7.92 MUSD+36.08%
5.82 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ESSA Pharma Stock analysis

What does ESSA Pharma do? ESSA Pharma Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of prostate cancer and other types of cancer. The company is headquartered in Vancouver, Canada and was founded in 2009. The history of ESSA Pharma Inc begins with the discovery of a new approach to treating prostate cancer by the company's founders. They discovered that a combination of an androgen receptor inhibitor and a NEDDylation signaling inhibitor could offer a new and effective approach to treating prostate cancer. Based on this discovery, they founded ESSA Pharma Inc to further develop this therapy. ESSA Pharma Inc's business model is based on the discovery, development, and commercialization of therapies for the treatment of prostate cancer and other types of cancer. The company has a pipeline of products in various clinical phases aimed at effectively combating prostate cancer and other types of cancer. ESSA Pharma Inc operates in two main divisions: research and development, and marketing and sales. The company's research and development department is dedicated to identifying and developing new compounds tailored to the specific needs of patients with prostate cancer. The company also works closely with researchers and physicians to test the efficacy of its products in treatment protocols and clinical practice. The second division of ESSA Pharma Inc deals with the marketing and sales of its products. Here, the company works closely with pharmaceutical manufacturers and other companies to market and sell its products worldwide. The company also has its own sales department that serves customers worldwide. ESSA Pharma Inc currently offers several products in different stages of clinical trials. These include EPI-506, an androgen receptor inhibitor currently being used in a Phase 1 study for the treatment of prostate cancer, and EPI-7386, a NEDDylation signaling inhibitor currently in a Phase 1 study for the treatment of prostate cancer. In addition, ESSA Pharma Inc has formed partnerships with other companies to further develop its technology platform and pipeline of cancer therapies. For example, the company is collaborating with Bayer Healthcare to advance the development of EPI-7386. Overall, ESSA Pharma Inc is an innovative and emerging biotech company focused on the development of therapies for the treatment of prostate cancer and other types of cancer. The company is pursuing an ambitious strategy and has already achieved promising results in the development of new compounds for the treatment of prostate cancer. ESSA Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ESSA Pharma stock

Enterprise Value (EV) of ESSA Pharma is -117.48 M USD in 2024.

Enterprise Value (EV) of ESSA Pharma changed from -138.56 M USD to -117.48 M USD, representing a -15.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) ESSA Pharma since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s ESSA Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ESSA Pharma

All Key Metrics — ESSA Pharma